Synonym
AGI-001; AGI001; AGI 001; MT102; MT-102; MT 102; Espindolol; l-Pindolol; (-)-Pindolol; S-Pindolol; (S)-pindolol; (S)-(-)-Pindolol
IUPAC/Chemical Name
(S)-1-((1H-indol-4-yl)oxy)-3-(isopropylamino)propan-2-ol
InChi Key
JZQKKSLKJUAGIC-NSHDSACASA-N
InChi Code
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3/t11-/m0/s1
SMILES Code
O[C@@H](CNC(C)C)COC1=CC=CC2=C1C=CN2
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
248.32
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, Beadle J, Anker SD; for and on behalf of the ACT‐ONE study group. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo- controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):355-65. doi: 10.1002/jcsm.12126. Epub 2016 Jul 1. PMID: 27386169; PMCID: PMC4929828.
2: Lainscak M, Laviano A. ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker. J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):400-2. doi: 10.1002/jcsm.12136. Epub 2016 Aug 5. PMID: 27625919; PMCID: PMC5011815.
3: Ebner N, Sliziuk V, Scherbakov N, Sandek A. Muscle wasting in ageing and chronic illness. ESC Heart Fail. 2015 Jun;2(2):58-68. doi: 10.1002/ehf2.12033. PMID: 28834653; PMCID: PMC6410534.
4: Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, Coats AJ, Anker SD, Springer J. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):149-58. doi: 10.1007/s13539-013-0125-7. Epub 2013 Nov 22. PMID: 24272787; PMCID: PMC4053568.
5: Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle. 2014 Jun;5(2):83-7. doi: 10.1007/s13539-014-0149-7. Epub 2014 May 28. PMID: 24865381; PMCID: PMC4053564.
6: Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):27-34. doi: 10.1007/s13539-014-0136-z. Epub 2014 Mar 5. PMID: 24595460; PMCID: PMC3953317.
